Asset profile

Palbociclib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — HR+/HER2- Metastatic Breast Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(38 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (11)

August 2026 (1)

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-08-24 · NCT04711252 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (3)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-09 · NCT05069038 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-09-30 · NCT03609047 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-09-30 · NCT03573648 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-11 · NCT02605486 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (6)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12 · NCT02738866 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-30 · NCT05909397 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-31 · NCT04553133 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-31 · NCT02465060 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2026-12-31 · NCT05226871 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (11)

January 2027 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-01-10 · NCT06207734 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-02-19 · NCT06065748 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (1)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-06 · NCT04920708 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-07 · NCT04841148 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-07-31 · NCT03304080 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-08-04 · NCT06188520 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-09-01 · NCT04985266 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-10-31 · NCT04563507 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (2)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2027-11-01 · NCT07299890 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2027-12-31 · NCT04567420 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (5)

January 2028 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting

Est. primary completion 2028-06-30 · NCT02942355 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-07-01 · NCT06062498 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2028 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2028-08-31 · NCT06377852 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (7)

March 2029 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2029 (2)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05 · NCT07174336 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)

Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-06-15 · NCT07748208 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2029 (2)

Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2029-07-01 · NCT07061717 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-07-13 · NCT04606446 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (1)

Phase 3HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (4)

July 2030 (3)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting

Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (1)

Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting

Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.